期刊文献+

HBV/HEV二价疫苗性抗原基因在E.coli中表达条件优化的初步研究

Preliminary study on optimization of expression condition of vector expressing HBV/HEV bivalent vaccinal antigen in E.coli
下载PDF
导出
摘要 为有效提高由乙型肝炎的S抗原基因和戊型肝炎ORF2编码区羧基末端414—606氨基酸基因片段构建的高效表达载体质粒PTΩ-T7SE在大肠杆菌BL21(DE3)中的表达效率,研究了质粒稳定性、葡萄糖质量分数、pH值、IPTG浓度、转接量、诱导时间、诱导温度、溶解氧对目的蛋白相对产量的影响,优化得到了较好的培养方法,使目的蛋白的相对含量达48.23%,菌体干重达0.5963g/L.结果表明,采用优化方法可制备较高纯度蛋白.本研究为大规模的发酵工艺提供了依据. In order to improve the production of interest protein expressed by plasmid PTΩ-T7SE, which contains both encoding genes. The S antigen of type B hepatitis and the 414-606 amino acide of C-teminal of E hepatitis are associated with protective immunity responses. Studied the effection of recombinant plasmid stability, glucose concentration, pH, IPTG concentrat, inoculum size, induction time, induction temperature, and weel as dissolved oxygen concentration during the expression of interest proteins. By the optimized method,the relative amount of interest proteins is 48.23% and the dry weight of thallus is 0. 596 3 g/L. Thus , this study is useful for large-scale production
出处 《东北师大学报(自然科学版)》 CAS CSCD 北大核心 2008年第1期125-130,共6页 Journal of Northeast Normal University(Natural Science Edition)
基金 吉林省科技发展计划项目(20050405-5) 吉林省教育厅资助项目(JYT200508)
关键词 HBV/HEV二价疫苗性抗原基因 发酵条件 优化 HBV/HEV bivalent vaccinal antigen fermentation condition optimization
  • 相关文献

参考文献1

二级参考文献21

  • 1冯仁伟.血清谷丙转氨酶测定[A].上海市医学化验所主编.临床生化检验(上册)[C].上海:上海科技出版社,1979.333-335.
  • 2Purdy M A, McCaustland K A, Krawczynski K, et al. Preliminary evidence that a trpE-HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV). J Med Virol, 1993,41:90~94.
  • 3Robinson R A, Burgess W H, Emerson S U, et al. Structural characterization of recombinant hepatitis E virus ORF2 proteins in baculovirus-infected insect cells. Protein Expression Purification, 1998, 12:75~84.
  • 4Tsarev S A, Tsareva T S, Emerson S U, et al. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Natl Acad Sci U S A. 1994, 91: 10198 ~10202.
  • 5Zhuang H, Cao X Y, Liu C B, et al. Epidemiology of hepatitis E in China. Gastroenterologia Japonica, 1999, 36(suppl3): 135~138.
  • 6Irshad M. Hepatitis E virus: an update on its molecular, clinical and epidemiological characteristics. Intervirology, 1999, 42:252~62
  • 7Zhang J Z, Ng M H, Xia N S, et al. Conformational antigenic determinants generated by interactions between a bacterially expressed recombinant peptide of the hepatitis E virus structural protein. J Med Virol, 2001, 64:125~132
  • 8Im S W, Zhang J Z, Zhuang H, et al. A bacterially expressed peptide prevents experimental infection of primates by the hepatitis E virus. Vaccine, 2001, 19:3726~3732
  • 9Tsarev S A, Tsareva T S, Emerson S U, et al. Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge.Vaccine. 1997, 15:1834~1838.
  • 10Zhang M, Emerson S U, Nguyen H, et al. Immunogenicity and protective efficacy of a vaccine prepared from 53 kD truncated hepatitis E virus capsid protein expressed in insect cells.Vaccine, 2001, 20:853~857.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部